About Ajax and our focus on hematologic malignancies Advances in molecular genetics and biology have led to the development of new classes of targeted therapies for the treatment of hematologic malignancies. However, many of these therapies, while selective for a particular drug target, often interact with other related proteins which can limit their efficacy and […]
Employees: 1-10
Total raised: $135M
Founded date: 2019
Investors 1
| Date | Name | Website |
| - | EcoR1 Capi... | ecor1cap.c... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 13.05.2024 | Series C | $95M | - |
| 01.06.2021 | - | $40M | - |
Mentions in press and media 7
| Date | Title | Description |
| 13.05.2024 | Ajax Therapeutics Raises $95M in Series C Financing | Ajax Therapeutics, a NYC- and Cambridge, MA-based biopharmaceutical company developing JAK inhibitors for patients with myeloproliferative neoplasms (MPNs), raised $95M in Series C funding. The round was led by Goldman Sachs Alternatives wi... |
| 02.06.2021 | SoFi flies in SPAC-tacular Nasdaq debut | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Good morning, all. This is Fortune finance reporter Rey Mashayekhi, filling in again for Lucinda.... |
| 02.06.2021 | SoFi flies in SPAC-tacular Nasdaq debut | Good morning, all. This is Fortune finance reporter Rey Mashayekhi, filling in again for Lucinda. There’s only one place to start as far as the capital markets were concerned Tuesday: the much-hyped—and, so far, rather successful—debut of S... |
| 01.06.2021 | Ajax Therapeutics, Inc. announced that it has received $40 million in funding from EcoR1 Capital, LLC, Boxer Capital LLC, Inning One Ventures, L.P., Schrödinger, Inc., Memorial Sloan Kettering Cancer ... | On June 1, 2021, Ajax Therapeutics, Inc. closed the transaction. The company received $40,000,000 in a round of funding led by new investor EcoR1 Capital, LLC. The transaction also included participation from new investor Boxer Capital LLC,... |
| 01.06.2021 | Ajax Therapeutics Raises $40M in Financing | Ajax Therapeutics, Inc., a NYC-based biotechnology company applying computational chemistry and structure-based technologies to develop novel small molecules for hematologic malignancies, completed a $40m financing. The round was led by Eco... |
| 01.06.2021 | Ajax Therapeutics Raises $40 Million Financing To Develop Novel Small Molecules Targeting Cytokine Signaling Pathways for Hematologic Malignancies | Ajax Therapeutics, Inc., a biotechnology company applying computational chemistry and structure-based technologies to develop novel small molecules for hematologic malignancies, today announced the completion of a $40 million financing. The... |
| - | Ajax Therapeutics | “About Ajax and our focus on hematologic cancers Advances in molecular genetics and biology have led to the development of new classes of targeted therapies for the treatment of hematologic cancers. However, many of these therapies, while s... |